Kornimate/medical-research-clean huggingface dataset:
diabetic foot ulcer imaging- study 2

Conditions: Foot Ulcer; Foot Ulcer, Diabetic

Summary: all study procedures will occur during one appointment. the research team will measure the size of the foot ulcer (if one is present) and multiple photos will be taken with a smart phone camera and thermal camera. demographic information will be obtained from the medical record.

the research procedures consist of a) a research assistant measuring the size of the foot ulcer (for ulcer patients), b) patients having pictures of their feet taken with a smart phone under 4 conditions- 1) photos taken by researchers, 2) photos taken by the patient by hand, 3) photos taken by the patient with a selfie stick, and 4) photos taken by a 3rd party (e.g., friend/family member of patient). if the patient is not able to take photographs under any of the conditions, that condition will be excluded. in addition to photos being taken with a smart phone, additional photos will be taken with a thermal camera by the research team to determine if there is a difference in ulcer size depending on type of camera used. it is anticipated that procedures will last between 15 and 45 minutes. there is no long-term follow-up. if a patient returns to the clinic they will be asked if they wish to complete all study procedures again. once the patient has left the clinic, the research team will check the medical record for: age, sex, race, ethnicity, bmi, co-morbidities, and zip code (to determine if patient lives in an urban or rural location).

Eligibility criteria:
inclusion criteria: * diagnosed with type 1 or type 2 diabetes * has a current foot lesion * receiving care through university of iowa hospitals and clinics (uihc) iowa river landing diabetes clinic, uihc internal medicine clinic, or uihc orthopedic clinic. exclusion criteria: * cognitive impairment that prevents consent * lack of fluency in speaking or understanding english * known aversion to research studies
adjuvant radiotherapy in high risk locally advanced dtc

Conditions: Thyroid Cancer

Summary: this study is a phase iii randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer. patients who meet the inclusion criteria were randomly assigned 1:1 to either the experimental group (adjuvant radiotherapy+rai) or the control group (rai), with lrfs as the primary endpoint of the study.


Eligibility criteria:
inclusion criteria: 1. the patient voluntarily joined this study and signed an informed consent form; 2. age: ≥ 14 years old,\<80 years old, male or female not limited; 3. histopathological diagnosis of differentiated thyroid cancer; 4. surgical total or near total thyroidectomy; 5. the surgery did not achieve r0 resection, and r1/ r2 resection was performed. the volume of residual tumor in r2 resected patients is less than 2cm3; 6. the main organ functions are normal; 7. good compliance and cooperation with follow-up. exclusion criteria: 1. previously received radiation therapy for the head and neck area; 2. differentiated thyroid cancer with poorly differentiated, or undifferentiated components; 3. there is distant metastasis; 4. previously received 131i treatment; 5. previously received or currently receiving targeted therapy, immunotherapy, chemotherapy; 6. within 5 years or simultaneously suffering from other active malignant tumors. cured local tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, can be included in the group; 7. pregnant or lactating women; 8. other physical illnesses that affect patients' ability to receive standard treatment; 9. according to the researchers' assessment, there may be other factors that could force the subjects to terminate the study, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the safety of the subjects or the collection of experimental data; 10. individuals with claustrophobia who are unable to undergo radiation therapy; 11. patients deemed unsuitable for inclusion by other attending physicians.
a study comparing efficacy of levodopa-carbidopa intestinal gel/carbidopa-levodopa enteral suspension and optimized medical treatment on dyskinesia in subjects with advanced parkinson's disease (dyscover)

Conditions: Parkinson's Disease (PD)

Summary: the primary objective of this study was to examine the effect of levodopa-carbidopa intestinal gel (lcig) compared with optimized medical treatment (omt) on dyskinesia in participants with advanced parkinson's disease (pd).

this was a phase 3b, open-label, randomized, multicenter, 12-week study. the study consisted of 3 sequential periods: screening, treatment, and follow-up. the omt group had the same schedule of visits/procedures throughout the study as the lcig treatment group, except for visits related to nasojejunal (nj)/percutaneous endoscopic gastrostomy (peg) procedures, titration of lcig, and follow-up period.

Eligibility criteria:
inclusion criteria: * participants must have a diagnosis of idiopathic parkinson's disease (pd) according to the united kingdom parkinson's disease society (ukpds) brain bank criteria * participants with advanced levodopa-responsive pd and persistent motor fluctuations who have not been controlled with optimized medical treatment (omt: the maximum therapeutic effect obtained with pharmacological antiparkinsonian therapies when no further improvement is expected with regard to any additional manipulations of levodopa and/or other antiparkinsonian medication based on the investigator's clinical judgment) * unified dyskinesia rating scale (udysrs) total score ≥ 30 at visit 3 exclusion criteria: * participant(s) treated with levodopa-carbidopa intestinal gel (lcig) previously * participant's pd diagnosis is unclear or there is a suspicion that the subject has a parkinsonian syndrome such as secondary parkinsonism (e.g. caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), parkinson-plus syndrome (e.g. multiple system atrophy, progressive supranuclear palsy, diffuse lewy body disease) or other neurodegenerative disease that might mimic the symptoms of pd * participant(s) has undergone neurosurgery for the treatment of parkinson's disease. * participant(s) has contraindications to levodopa (e.g. narrow angle glaucoma, malignant melanoma) * participant(s) experiencing clinically significant sleep attacks or clinically significant impulsive behavior (e.g. pathological gambling, hypersexuality) at any point during the three months prior to the screening evaluation as judged by the principal investigator

Keywords: carbidopa levodopa efficacy levodopa-carbidopa intestinal gel advanced parkinson's disease
adjuvant gemcitabine and cisplatin followed by chemoradiation for resected pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this is a phase ⅱ trial of postoperative adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiation with gemcitabine in patients with resected pancreatic cancer.

the primary study objective is to evaluate recurrence/metastasis free survival at 12 months with postoperative adjuvant treatment incorporating gemcitabine plus cisplatin chemotherapy followed by chemoradiation with gemcitabine followed by maintenance chemotherapy with gemcitabine.

Eligibility criteria:
inclusion criteria: 1. give written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice. 2. be between 18 and 75 years of age. 3. patients who are ambulatory and have a ecog performance status of 0-2. 4. histologically confirmed pancreatic adenocarcinoma. 5. received curative resection (r0 resection) of stage 1b \~ 2b pancreatic cancer (according to ajcc staging, 6th edition - appendix 1), no more than 8 weeks has elapsed since the time of operation. 6. wbc at least 3,000/mm3 or absolute neutrophil count at least 1,500/mm3. platelet count at least 100,000/mm3. 7. bilirubin less than 2.0 mg/dl, ast less than 3 times upper limit of normal (uln). serum creatinine no greater than 1.5 times uln. exclusion criteria: 1. pregnant or lactating woman. 2. woman of childbearing potential with either a positive or no pregnancy test at baseline. 3. woman of childbearing potential not using a reliable and appropriate contraceptive method (postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential). 4. sexually active males unwilling to practice contraception during the study. 5. prior chemotherapy for the treatment of pancreatic carcinoma. 6. radiotherapy incorporating radiation fields of more than 25% of active bone marrow. 7. history of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix. 8. clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease, and cardiac arrhythmias not well controlled with medication). 9. participation in any investigational drug study within four weeks preceding the start of study treatment. 10. serious, uncontrolled, intercurrent infection(s). 11. other significant medical conditions that would, in the judgment of the investigator, make administration of study drug unsafe.

Keywords: resected pancreatic cancer
effect of lcz696 on urinary microalbumin and pulse wave velocity in perimenopausal patients with hypertension

Conditions: Hypertension

Summary: to explore the efficacy of sacubitril/valsartan in the treatment of perimenopausal hypertensive patients, as well as the difference between the antihypertensive efficacy and valsartan, the therapeutic effect of its exposure to different factors and the protection of target organs.to provide reference for the clinical treatment of perimenopausal hypertension patients with shakubactrivalsartan. 1. to evaluate the effects of sacubitril/valsartan on urinary microalbumin and pulse wave velocity in perimenopausal hypertension patients. 2. to evaluate the clinical application of sacubitril/valsartan in the treatment of perimenopausal hypertension, so as to improve the blood pressure management ability and control rate of patients with such hypertension.

a total of 264 cases of perimenopausal patients with essential hypertension who were admitted to department of cardiology, second hospital of lanzhou university,from january, 2020 to march,2021 will be enrolled and randomized to receive once-daily treatment with 100-400 mg of sacubitril/valsartan or 80-320 mg of valsartan.the general information, menstrual history, cardiac ultrasound, urinal-renal function, pwv, baseline blood pressure, post-medication blood pressure, whether to use antihypertensive drugs and the type of antihypertensive drugs of the patients were enrolled.after 12 weeks of drug intervention, left ventricular mass indexwere measured by cardiac ultrasound, pwv, urinary microalbinin, 24-hour ambulatory blood pressure monitoring, biochemical indicators will be collected.spss22.0 statistical software was used for statistical analysis of pwv, urinary microalbumin, blood pressure and other results by paired data t-test, and the chi-square test was used for non-count data.

Eligibility criteria:
inclusion criteria: 1. patients with essential hypertension（sbp\>140 and \ 90 and \<110 mmhg)）were diagnosed according to the hypertension diagnostic criteria of the chinese guidelines for hypertension (2018 revised edition)； 2. female aged 45-55 years old and meeting the perimenopausal criteria in the strae+10; 3. no other complications, no treatment or ongoing antihypertensive therapy (sbp ≥140mmhg or diastolic bp ≥90mmhg)； 4. agree to participate in the study and sign the informed consent； exclusion criteria: 1. secondary hypertension； 2. history of angioedema； 3. heart failure nyha grade iii or above (excluding grade iii)； 4. liver and kidney dysfunction (alt or ast≥ three times the upper limit of normal value, that is, alt≥120u/l,ast≥120u/l, creatinine clearance \< 30ml/min); 5. hyperkalemia (serum potassium ≥5.5mmol/l); 6. moderate or above anemia (hgb≤90g/l); 7. bilateral renal artery stenosis; 8. history of stroke;

Keywords: perimenopausal hypertensive sacubitril/valsartan pulse wave velocity urinary microalbuminuria
hiv, equity, and addiction training (heat) program

Conditions: Substance Use Disorders; Hiv; Opioid Use Disorder; Stimulant Use (Diagnosis)

Summary: this project is a pilot study to determine the feasibility and acceptability of a telemedicine intervention for substance use disorder service delivery in diverse people living with hiv in alabama.

the contemporary drug crisis and the covid-19 pandemic have exposed the complex syndemics of addiction and infectious diseases: rising rates of substance use disorder (sud) have outpaced our ability to respond with a limited healthcare workforce and public health capacity. sud is increasing in those living with and at risk for hiv, and infectious consequences of sud, like hepatitis c, have continued, unmitigated, in rural parts of the u.s. where many states lack medicaid expansion, syringe service programs, and public health infrastructure to respond to the drug crisis and comorbid infections. systemic racism and regressive policies in the deep south criminalize people who use drugs, creating additional barriers to care, hiv prevention, and addiction treatment. as a result, people who use drugs rarely receive comprehensive addiction and hiv treatment. yet telemedicine has the potential to overcome these barriers and bypass the constraints of a brick-and-mortar clinic to link vulnerable people, including those with hiv, to care. although telemedicine has become mainstream in recent years, few studies have evaluated telemedicine for sud in the deep south from the perspective of patients and providers.

Eligibility criteria:
inclusion criteria: * receiving services at hiv clinics in alabama * reported opioid and/or stimulant misuse * 18 years of age or older exclusion criteria: * receipt of sud clinical care other than through hiv provider/clinic in the last 3 months * inability to engage in interviews independently without support (e.g., cognitive impairment) * currently psychotic * actively suicidal: presents with a suicide attempt or suicidal ideation

Keywords: alabama ryan white clinics hiv treatment substance use disorder treatment telemedicine
results at 10 to 14 years after microfracture in the knee

Conditions: Articular Chondral Defect

Summary: articular cartilage lesions are commonly occurring. in a prospective study of 1,000 knee arthroscopies focal chondral or osteochondral defects were found in 19% of the patients (hjelle 2002). chronic articular cartilage defects do not heal spontaneously. however, acute traumatic osteochondral lesions or surgically inflicted lesions extending into subchondral bone, e.g. by drilling (pridie 1959), spongialization, abrasion or microfracture with an angled awl (rodrigo 1994) causing the release of pluripotent mesenchymal stem cells from the bone marrow, may heal with repair tissue consisting of fibrous tissue, fibrocartilage or hyaline-like cartilage. the microfracture technique causes little damage to the subchondral bone plate and the risk of heat necroses caused by drilling or abrasion is eliminated. the quality of the repair tissue after these bone marrow stimulating techniques depends on various factors including the species and age of the individual, the size and localization of the defect, the surgical technique, e.g., how the subchondral bone plate is treated, and the postoperative rehabilitation protocol. microfracture has been used in small traumatic defects in young sporting individuals (steadman 2003) as well as in larger osteoarthritic lesions in older patients (miller 2004, steadman 2007). the purpose of the present study was to investigate the long-term clinical outcome 10 to 14 years after microfracture of articular cartilage defects in the knee and possible predictors of good and poor outcomes.


Eligibility criteria:
inclusion criteria: * patients with symptomatic focal full-thickness chondral lesions verified by arthroscopic examination and a minimum of 10-year follow-up. exclusion criteria: * exclusion criteria were joint space narrowing (\< 4 mm) on standard antero-posterior x-ray films, * axial malpositioning, * ligament instabilities or inability to follow the rehabilitation protocol.

Keywords: chondral defect microfracture arthroscopy cartilage repair outcome study lysholm score
intracranial pressure in experimental models of headache

Conditions: High Altitude Headache

Summary: the purpose of this study is to determine whether increased pressure in the head is elevated in people who suffer from high altitude headache. we hypothesise that head pressure will be elevated in people with high altitude headache.

high altitude headache is the primary symptom of acute mountain sickness. however, at present the reason why some individuals suffer from high altitude headache and others do not remains unknown. it is widely believed that elevated pressure within the brain leads to stretching of pain sensitive fibres and thus headache. however, evidence of raised intracranial pressure during high altitude headache is currently unavailable. therefore, this study aims to examine a proxy measure of intracranial pressure (optic nerve sheath diameter) in persons visiting high altitude, half of whom have been given the drug acetazolamide that is known to reduce headache symptoms.

Eligibility criteria:
inclusion criteria: * member of the italian high altitude research expeditions exclusion criteria: * are under the age of 18years; * sulfonamide allergy * liver or kidney disfunction * have any other uncontrolled medical condition * or are unable to give consent.

Keywords: high altitude headache; intra-cranial pressure; hypoxia
integrating palliative care and modern palliative care tools into the care of patients with pancreas cancer

Conditions: Pancreas Cancer

Summary: the main purpose of this study is to evaluate the acceptance by patients with metastatic pancreas cancer of integrating palliative care with usual cancer treatment. palliative care intervention will involve use of pancreas cancer-specific decision aides (ipc3)about prognosis, treatment choices, and advance care planning for patients facing a treatment decision as well as symptom assessments. we hypothesize that palliative care consultations with ipc3 will be accepted, symptoms can be diminished, information can be received in a way that improves choices, and that the quality of care can be improved.

* each patient undergoing treatment at johns hopkins for metastatic pancreas cancer will receive palliative care support during their course to include: palliative care consultation early in their treatment course; patient decision aids that give survival, treatment benefits and risks; suggestions to complete such tasks as advance directives, durable power of medical attorney, wills, family and spiritual reviews as recommend by the american society of clinical oncology; and when indicated, transition to hospice. * patient will have an ipad for their visit, and a corresponding website to print information. * each patient will assess their distress with the distress thermometer; symptoms with the condensed memorial symptom assessment scale and a depression screen. this information will be given to the health care practitioner before the patient visit. * patients facing a treatment decision will receive a patient information program link (or paper for those unable to work on the ipad) to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy. this will then give transition "prompts" to encourage thinking about advance directives, durable power of medical attorney, use of hospice, and doing a life review. * we will also offer a hospice information visit when patient has - in the projection of the team or treating physician - 3 to 6 months to live. * the palliative care team will meet at least monthly with each of the enrolled patients. * participants will be followed for as long as he or she is alive before receiving hospice care.

Eligibility criteria:
inclusion criteria: * all patients with metastatic pancreas cancer will be eligible, ages 18 and above. * there is no limit to the amount of prior therapy for metastatic disease. * ability to understand and the willingness to sign a written informed consent document and to answer a questionnaire. * english speakers. exclusion criteria: * patients who have tumors other than metastatic pancreas cancer. * patients who actively decline participation or who are judged to be in distress before the interview. * patients who are pregnant.

Keywords: palliative care decision aid
home care needs and current nursing status of patients with amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of this study is to comprehensively investigate and analyze the home care needs and status quo of als patients in china, and to clarify their home care needs and status quo, so as to provide reference for the development of home care service planning and policy measures for als patients.

amyotrophic lateral sclerosis (als) is the most common type of motor neuron disease. it is common in middle-aged and elderly people. progressive skeletal muscle weakness, atrophy, fascicular fibrillation, bulbar paralysis and pyramidal tract sign are the main clinical manifestations. the survival time is usually 3-5 years. as the pathogenesis of als is not fully understood, there is no specific treatment for als. the clinical treatment mode of most patients with als is hospitalization at the end of the disease and maintenance treatment at home during the disease progression. at present, there are few reports on the home care needs and nursing status of als patients in china. this study is a cross-sectional survey. based on consulting the relevant literature and consulting experts' opinions, the researchers designed the questionnaire of home care needs and nursing status of als patients, the convenience sampling method was used to select 126-252 als outpatients, 126-252 als inpatients, and 126-252 als family members from a third class a general hospital in beijing. the needs and status of home care of als patients in china were comprehensively investigated and analyzed, and the needs and status of home care were clarified, so as to provide reference for the development of home care service planning and policy measures for als patients.

Eligibility criteria:
inclusion criteria: - the inclusion criteria of als patients: 1. they met the diagnostic criteria of chinese guidelines for the diagnosis and treatment of amyotrophic lateral sclerosis; ② receiving care at home; ③ no cognitive impairment (if the patient is unable to talk and write due to illness, the family members can express it for the patient); ④ informed consent, willing to participate in this study; ⑤ no mental illness. the inclusion criteria of caregivers: ① the primary caregiver designated by the patient was responsible for the primary care; * they are relatives of patients; * no payment for care; ④ informed consent, willing to participate in this study; * no mental illness; ⑥ there was no cognitive impairment. exclusion criteria: - exclusion criteria of als patients: ① severe physical diseases, such as malignant tumor, liver and kidney dysfunction, etc; ② they are participating in other intervention projects. exclusion criteria of caregivers: * severe physical diseases, such as malignant tumor, liver and kidney dysfunction, etc; ② they are participating in other intervention projects.